Biogen reports strong enrollment progress in the AMETHYST clinical trial testing litifilimab in cutaneous lupus erythematosus ...

Unprepared for a recent hospitalization, columnist Candace Semien is now pre-packing essential items into a go bag.

Damage to the body’s organs from lupus, an autoimmune disorder caused by a patient’s own immune system attacking healthy tissues, can result in a wide range of symptoms, from skin issues to kidney and ...

Summer is officially here, and while I’m trying to shield myself from the sun, practically everyone I know is talking about their travel plans. If you follow my writing, you know I’m fascinated by ...

Lupus is an autoimmune disorder wherein the immune system attacks the body’s own healthy tissue. A diagnosis can be challenging as there is no single, definite test available. Furthermore, lupus ...

A Phase 2 clinical trial testing Galápagos‘ experimental oral therapy GLPG3667 in people with systemic lupus erythematosus (SLE) has failed to meet its main goal, although some promising trends were ...

Lupus News Today is a digital platform intended to provide the lupus community with the most recent news and information, as well as first-hand community perspectives from our patient and caregiver ...

If you're living with a chronic illness like lupus, workplace accommodations are your legal right, explains columnist.

The Department of Defense recently announced the 13 winners of the 2017 Lupus Research Program, who received a combined total of $5 million to fund lupus research projects of both scientific and ...

Lupus can affect patients in many ways, and although no two patients will share exactly the same symptoms, there are some common symptoms that most people know of, like a butterfly rash, joint pain, ...

The U.S. Food and Drug Administration (FDA) has approved Gazyva (obinutuzumab) as an add-on treatment for adults with lupus nephritis, a form of lupus marked by kidney damage. Lupus is an autoimmune ...

Treatment with dapirolizumab pegol is better than a placebo at controlling disease activity in people with systemic lupus erythematosus (SLE), according to new results from a Phase 3 clinical trial.